Omnicell, Inc. (NASDAQ:OMCL) Shares Sold by Dynamic Technology Lab Private Ltd

Dynamic Technology Lab Private Ltd reduced its stake in Omnicell, Inc. (NASDAQ:OMCL) by 58.1% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 11,092 shares of the company’s stock after selling 15,351 shares during the period. Dynamic Technology Lab Private Ltd’s holdings in Omnicell were worth $484,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also made changes to their positions in OMCL. Victory Capital Management Inc. raised its holdings in shares of Omnicell by 11,982.3% in the 3rd quarter. Victory Capital Management Inc. now owns 1,148,426 shares of the company’s stock worth $50,071,000 after purchasing an additional 1,138,921 shares in the last quarter. Federated Hermes Inc. raised its holdings in shares of Omnicell by 1,113.6% in the 2nd quarter. Federated Hermes Inc. now owns 991,151 shares of the company’s stock worth $26,830,000 after purchasing an additional 909,480 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. bought a new stake in shares of Omnicell in the 3rd quarter worth approximately $32,721,000. Pacer Advisors Inc. raised its holdings in shares of Omnicell by 32.6% in the 2nd quarter. Pacer Advisors Inc. now owns 2,070,434 shares of the company’s stock worth $56,047,000 after purchasing an additional 508,789 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. raised its holdings in shares of Omnicell by 750.5% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 294,037 shares of the company’s stock worth $12,820,000 after purchasing an additional 259,463 shares in the last quarter. 97.70% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research firms recently commented on OMCL. JPMorgan Chase & Co. boosted their target price on shares of Omnicell from $37.00 to $44.00 and gave the stock a “neutral” rating in a report on Thursday, November 21st. Benchmark reiterated a “buy” rating and issued a $48.00 target price on shares of Omnicell in a report on Wednesday, October 9th. StockNews.com lowered shares of Omnicell from a “buy” rating to a “hold” rating in a report on Wednesday. Bank of America restated a “neutral” rating and set a $57.00 price target (up previously from $44.00) on shares of Omnicell in a report on Thursday, October 31st. Finally, Craig Hallum boosted their price target on shares of Omnicell from $45.00 to $64.00 and gave the company a “buy” rating in a report on Thursday, October 31st. Five investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $52.00.

Omnicell Price Performance

OMCL stock opened at $46.59 on Friday. Omnicell, Inc. has a 52-week low of $25.12 and a 52-week high of $55.74. The company’s 50 day simple moving average is $44.55 and its 200-day simple moving average is $37.94. The firm has a market capitalization of $2.16 billion, a P/E ratio of -119.46, a P/E/G ratio of 36.82 and a beta of 0.81.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.